

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide wherein the sequence of the polynucleotide consists of the sequence provided in SEQ ID NO:305 or the full length complement thereof;

(b) a polynucleotide that is up to 2000 nucleotides in length and comprises the sequence provided in SEQ ID NO:305 or the full length complement thereof; and

(c) a polynucleotide wherein the sequence of the polynucleotide consists of a fragment of the sequence provided in SEQ ID NO:305 or the full length complement thereof, wherein the fragment is 50-400 nucleotides in length, and wherein the fragment can be used to detect the presence of the polynucleotide provided in SEQ ID NO:305 in a biological sample comprising the sequence provided in SEQ ID NO: 305, or the complement thereof.

2. (Canceled).

3. (Previously Presented) An expression vector comprising the polynucleotide of claim 1 operably linked to an expression control sequence.

4. (Original) A host cell transformed or transfected with an expression vector according to claim 3.

5.-21. (Canceled)

22. (Previously Presented) A composition comprising the polynucleotide of claim 1 in combination with a physiologically acceptable carrier.

23. (Previously Presented) A composition comprising the polynucleotide of claim 1 in combination with an immunostimulant.

24. (New) An isolated polynucleotide according to claim 1(c), wherein the sequence consists of SEQ ID NO:52.